Generic user fee survey
Generic Pharmaceutical Association is surveying members' on user fees for ANDAs. Companies are being asked whether they would accept fees under any condition. The survey, which is due back Feb. 4, also asks firms to describe "the benefits to the generic industry that you would want to see accompany a user fee if one were to be implemented by Congress"...
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?